Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study

Vasculitis Adult Male Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibodies, Antineutrophil Cytoplasmic Cohort Studies 03 medical and health sciences 0302 clinical medicine Risk Factors Pneumonia, Bacterial Humans Lung Aged Retrospective Studies Middle Aged Diseases of the genitourinary system. Urology Anti-neutrophil cytoplasmic antibody 3. Good health Risk factors Female RC870-923 Infection Immunosuppressive Agents Research Article Follow-Up Studies
DOI: 10.1186/s12882-018-0933-2 Publication Date: 2018-06-14T08:35:05Z
ABSTRACT
Severe infections are common complications of immunosuppressive treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with renal involvement. We investigated the clinical characteristics and risk factors severe infection in Chinese patients AAV after therapy. A total 248 a new diagnosis ANCA-associated were included this study. The incidence, time, site, by induction therapies analysed. Multivariate Cox proportional hazards models used to calculate hazard ratios (HRs) 95% confidence intervals (CI). 103 episodes identified 86 (34.7%, 86/248) during median follow-up 15 months. incidence therapy was 38.5% corticosteroids (CS), 39.0% CS+ intravenous cyclophosphamide (IV-CYC), 33.8% mycophenolate mofetil 22.5% CS + tripterygium glycosides, 76 (73.8%) occurred within 6 months, while 66 (64.1%) 3 Pneumonia (71.8%, 74/103) most frequent type infection, main pathogenic spectrum bacteria (78.6%), fungi (12.6%), viruses (8.7%). associated age at time (HR = 1.003, CI 1.000–1.006), smoking 2.338, 1.236–4.424), baseline secrum creatinine (SCr) ≥5.74 mg/dl 2.153, 1.323–3.502), CD4+ T cell< 281 μl 1.813, 1.133–2.900), regimen 1.951, =1.520–2.740). Twelve (13.9%) died pneumonia. rate high AAV. Bacterial pneumonia encountered. Age diagnosis, smoking, SCr mg/dl, μl, IV-CYC as infection.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (32)
CITATIONS (57)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....